VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+10.73%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$188M
AUM Growth
+$30.7M
(+19%)
Cap. Flow
+$19.9M
Cap. Flow
% of AUM
10.59%
Top 10 Holdings %
Top 10 Hldgs %
6.1%
Holding
495
New
69
Increased
189
Reduced
162
Closed
73
Top Buys
| 1 |
Palantir
PLTR
|
$1.01M |
| 2 |
BlackRock TCP Capital
TCPC
|
$1M |
| 3 |
Host Hotels & Resorts
HST
|
$993K |
| 4 |
DFS
Discover Financial Services
DFS
|
$989K |
| 5 |
Public Storage
PSA
|
$931K |
Top Sells
| 1 |
Burlington
BURL
|
$962K |
| 2 |
Prologis
PLD
|
$773K |
| 3 |
Booking.com
BKNG
|
$734K |
| 4 |
Eaton
ETN
|
$720K |
| 5 |
TE Connectivity
TEL
|
$708K |
Sector Composition
| 1 | Healthcare | 21.52% |
| 2 | Financials | 20.16% |
| 3 | Technology | 16.46% |
| 4 | Industrials | 8.76% |
| 5 | Energy | 7.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Biomea Fusion
BMEA
$112M
| $92.2K | 0.05% |
6,166
-423
| -6% | -$6.32K |
|
377
Zentalis Pharmaceuticals
ZNTL
$125M
| $91.3K | 0.05% |
5,790
-399
| -6% | -$6.29K |
|
378
Replimune Group
REPL
$478M
| $91.2K | 0.05% |
11,165
-766
| -6% | -$6.26K |
|
379
Recursion Pharmaceuticals
RXRX
$2B
| $90.7K | 0.05% |
9,093
-622
| -6% | -$6.2K |
|
380
Xenon Pharmaceuticals
XENE
$3.01B
| $90.5K | 0.05% |
2,103
-142
| -6% | -$6.11K |
|
381
Xencor
XNCR
$608M
| $90.4K | 0.05% |
4,087
-276
| -6% | -$6.11K |
|
382
Terns Pharmaceuticals
TERN
$627M
| $87.7K | 0.05% |
13,372
-915
| -6% | -$6K |
|
383
Regenxbio
RGNX
$485M
| $87.6K | 0.05% |
4,159
-288
| -6% | -$6.07K |
|
384
Vir Biotechnology
VIR
$729M
| $87.4K | 0.05% |
8,630
-591
| -6% | -$5.99K |
|
385
Arrowhead Research
ARWR
$3.97B
| $86.7K | 0.05% |
3,031
-212
| -7% | -$6.06K |
|
|
EXAI
386
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $84K | 0.04% |
14,684
-1,008
| -6% | -$5.77K |
|
387
Scholar Rock
SRRK
$3.06B
| $83K | 0.04% |
4,671
-317
| -6% | -$5.63K |
|
388
Rocket Pharmaceuticals
RCKT
$351M
| $82.5K | 0.04% |
3,063
-211
| -6% | -$5.68K |
|
389
Nuvalent
NUVL
$5.88B
| $82.3K | 0.04% |
1,096
-76
| -6% | -$5.71K |
|
390
Neumora Therapeutics
NMRA
$272M
| $81.4K | 0.04% |
5,918
-410
| -6% | -$5.64K |
|
|
SLRN
391
DELISTED
ACELYRIN
SLRN
| $80.3K | 0.04% |
11,901
-816
| -6% | -$5.51K |
|
|
VERV
392
DELISTED
Verve Therapeutics
VERV
| $80.3K | 0.04% |
6,046
-419
| -6% | -$5.56K |
|
393
Olema Pharmaceuticals
OLMA
$553M
| $79.6K | 0.04% |
7,030
-485
| -6% | -$5.49K |
|
394
Dynavax Technologies
DVAX
$1.18B
| $79.2K | 0.04% |
6,382
-441
| -6% | -$5.47K |
|
395
Viridian Therapeutics
VRDN
$1.5B
| $78.4K | 0.04% |
4,479
-308
| -6% | -$5.39K |
|
396
Pliant Therapeutics
PLRX
$108M
| $77K | 0.04% |
5,167
-354
| -6% | -$5.28K |
|
397
Denali Therapeutics
DNLI
$2.25B
| $76.6K | 0.04% |
3,735
-259
| -6% | -$5.32K |
|
398
MoonLake Immunotherapeutics
MLTX
$3.8B
| $75.5K | 0.04% |
1,504
-101
| -6% | -$5.07K |
|
|
BLTE
399
Belite Bio
BLTE
$2.19B
| $75.2K | 0.04% |
1,959
-137
| -7% | -$5.26K |
|
400
Intellia Therapeutics
NTLA
$1.27B
| $74.8K | 0.04% |
2,719
-187
| -6% | -$5.14K |
|